Dario Marangoni

Dr. Dario Marangoni


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
DMDario Marangoni
Dario Marangoni
Benedetto FalsiniBenedetto Falsini
Benedetto Falsini
MPMarco Piccardi
Marco Piccardi
LALucia Ambrosio
Lucia Ambrosio
AMAngelo maria Minnella
Angelo maria Minnella
ETTORE CAPOLUONGOETTORE CAPOLUONGO
ETTORE CAPOLUONGO
To determine whether the functional effects of oral supplementation with Saffron, a natural compound that proved to be neuroprotective in early age-related macular degeneration, are influenced by complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) risk genotypes.

15 October 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
MPMarco Piccardi
Marco Piccardi
AFAntonello Fadda
Antonello Fadda
FMFrancesco Martelli
Francesco Martelli
DMDario Marangoni
Dario Marangoni
AMAdriano Magli
Adriano Magli
Benedetto FalsiniBenedetto Falsini
Benedetto Falsini
Retinal oxidative damage, associated with an ATP-binding cassette, sub-family A, member 4, also known as ABCA4 gene mutation, has been implicated as a major underlying mechanism for Stargardt disease/fundus flavimaculatus (STG/FF). Recent findings indicate that saffron carotenoid constituents crocins and crocetin may counteract retinal oxidative damage, inflammation and protect retinal cells from apoptosis. This pilot study aimed to evaluate central retinal function following saffron supplementation in STG/FF patients carrying ABCA4 mutations. Methods: in a randomized, double-blind, placebo-controlled study (clinicaltrials.gov: NCT01278277), 31 patients with ABCA4-related STG/FF and a visual acuity >0.25 were randomly assigned to assume oral saffron (20 mg) or placebo over a six month period and then reverted to P or S for a further six month period. Full ophthalmic examinations, as well as central 18° focal electroretinogram (fERG) recordings, were performed at baseline and after six months of either saffron or placebo. The fERG fundamental harmonic component was isolated by Fourier analysis. Main outcome measures were fERG amplitude (in µV) and phase (in degrees). The secondary outcome measure was visual acuity. Results: supplement was well tolerated by all patients throughout follow-up. After saffron, fERG amplitude was unchanged; after placebo, amplitude tended to decrease from baseline (mean change: −0.18 log µV, p < 0.05). Reverting the treatments, amplitude did not change significantly. fERG phase and visual acuity were unchanged throughout follow-up. Conclusions: short-term saffron supplementation was well tolerated and had no detrimental effects on the electroretinographic responses of the central retina and visual acuity. The current findings warrant further long-term clinical trials to assess the efficacy of saffron supplementation in slowing down the progression of central retinal dysfunction in ABCA4-related STG/FF.

23 January 2012 in Acta Ophthalmologica
Verified
Journal Article
Open access
PDF file
DMDario Marangoni
Dario Marangoni
Benedetto FalsiniBenedetto Falsini
Benedetto Falsini
ACAlberto Colotto
Alberto Colotto
TSTommaso Salgarello
Tommaso Salgarello
GAGianmario Anselmi
Gianmario Anselmi
CRCharles E. Riva
Charles E. Riva
: Purpose:  To assess subfoveal choroidal blood flow (ChBF) in patients with early manifest glaucoma (EMG) and to compare blood flow with functional measures of central retinal integrity, standard automated perimetry (SAP) and pattern electroretinogram (PERG).Methods:  Subfoveal ChBF was determined by confocal, real‐time laser Doppler flowmetry in 24 patients with EMG [>−6 dB mean deviation (MD), age range: 29–77 years, visual acuity: 20/25–20/20] and 23 age‐matched control subjects. All patients had a therapeutically (topical beta‐blockers with or without prostaglandin analogues) controlled intraocular pressure (IOP < 20 mmHg). Subfoveal choroidal blood volume (ChBVol), velocity (ChBVel) and ChBF were determined as the average of three 60 second recordings. In all patients and controls, the PERG and SAP (Humphrey 30‐2), following standardized protocols, were also recorded.Results:  In patients with EMG, reductions in average ChBVel and ChBF were roughly equal, respectively, by 30% and 33.4% (p < 0.01), when compared to control subjects, so that there was no significant difference in ChBVol between the two groups. Pattern electroretinogram amplitudes were reduced by 46% (p < 0.01) in patients compared to controls. No correlation was found between any of the ChBF parameters and PERG amplitude, or Humphrey 30‐2 MD and pattern standard deviation.Conclusion:  The results suggest a significant alteration of both ChBVel and ChBF in EMG, which does not appear to be associated with the severity of central retinal dysfunction. These findings may contribute to a better understanding of the pathophysiology of early glaucomatous damage in EMG and have implications for the treatment of this pathologic condition.